Lake Street analyst Brooks O’Neil initiated coverage of Organogenesis with a Buy rating and $5 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ORGO:
- Organogenesis Shareholders Affirm Governance and Strategy
- Organogenesis Holdings Inc. to Participate in the Truist Securities MedTech Conference
- Organogenesis sees FY24 revenue $445M-$470M, consensus $454.69M
- Organogenesis reports Q1 EPS (2c), consensus (3c)
- Organogenesis achieves primary endpoint in Phase 3 trial of ReNu